Drugs Made In America Acquisition Corp. (DMAA) - Dilution Analysis

10-Q filing | 23.0M shares outstanding

10-K filing | 33.7M shares outstanding

10-Q filing | 33.5M shares outstanding

10-Q filing | 33.5M shares outstanding

10-Q filing | 33.5M shares outstanding

10-K filing | 33.5M shares outstanding

8-K filing: Drugs Made In America Acquisition Corp. consummated its initial public offering of 20,000,000 units at $10.00 per unit, generating gross proceeds of $200,000,000, and also consummated a private placement in which Drugs Made In America Acquisition LLC purchased 400,000 units at $10.00 per unit, for $4,000,000; the underwriters exercised the over-allotment option in full for 3,000,000 additional Units at $10.00 per unit, resulting in total gross proceeds of $30,000,000, and the company consummated the private sale of an additional 30,000 Private Units, generating gross proceeds of $300,000. ($234.3M proceeds)

8-K filing: Drugs Made In America Acquisition Corp. consummated its initial public offering of 20,000,000 units at $10.00 per unit, generating gross proceeds of $200,000,000, and a private placement in which Drugs Made In America Acquisition LLC purchased 400,000 private units at $10.00 per unit, for $4,000,000. ($204.0M proceeds)

8-K filing: Drugs Made In America Acquisition Corp. consummated its IPO of 20,000,000 units at $10.00 per unit, generating gross proceeds of $200,000,000 and consummated the private placement with the Sponsor of 400,000 units at a price of $10.00 per Private Unit, generating total proceeds of $4,000,000. ($204.0M proceeds)

POS AM filing: This is a POS AM filing for an initial public offering of 20,000,000 units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination, with Drugs Made In America Acquisition Corp. seeking to consummate a business combination in the pharmaceutical industry.

POS AM filing: This is a POS AM filing for an initial public offering of 20,000,000 units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-eighth of an ordinary share, with the underwriters having a 45-day option to purchase up to an additional 3,000,000 units to cover over-allotments.

S-1/A filing: This is an S-1/A filing related to removing unsold securities from registration at the termination of the offering and determining liability under the Securities Act of 1933 for purchasers.

S-1/A filing: This S-1/A filing registers the initial public offering of Drugs Made In America Acquisition Corp., a blank check company offering 20,000,000 units at $10.00 each, with each unit comprising one ordinary share and one right to receive one-eighth of an ordinary share upon consummation of an initial business combination.

S-1/A filing: This is an S-1/A filing for Drugs Made In America Acquisition Corp.'s initial public offering of 20,000,000 units, with each unit consisting of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination, at an offering price of $10.00 per unit, seeking to raise $200,000,000.

S-1/A filing: This S-1/A filing is for an initial public offering of 20,000,000 units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-eighth of an ordinary share, by Drugs Made In America Acquisition Corp., a newly incorporated blank check company.

S-1/A filing: This S-1/A filing relates to an initial public offering of 50,000,000 units at $10.00 per unit by Drugs Made In America Acquisition Corp., a blank check company focusing on the pharmaceutical industry, with each unit consisting of one ordinary share and one right to receive one-tenth of an ordinary share upon a business combination.

S-1/A filing: Drugs Made In America Acquisition Corp. is offering 50,000,000 units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share, and is also conducting a private placement of 450,000 units at $10.00 per unit.

S-1 filing: This is an S-1 filing for an initial public offering of Units for a blank check company, Drugs Made In America Acquisition Corp., with the goal of effecting a business combination within the pharmaceutical industry.